Main Article Content
Bone marrow derived myeloid cells progressively accumulate in tumors, where they establish an inflammatory microenvironment that is favorable for tumor growth and spread. These cells are comprised primarily of monocytic and granulocytic myeloid derived suppressor cells (MDSCs) or tumor-associated macrophages (TAMs), which are generally associated with a poor clinical outcome. MDSCs and TAMs promote tumor progression by stimulating immunosuppression, neovascularization, metastasis and resistance to anti-cancer therapy. Strategies to target the tumor-promoting functions of myeloid cells could provide substantial therapeutic benefit to cancer patients.
How to Cite
SCHMID, Michael C; VARNER, Judith A. Myeloid cells in tumor inflammation. Vascular Cell, [S.l.], v. 4, n. 1, p. 14, sep. 2012. ISSN 2045-824X. Available at: <https://vascularcell.com/index.php/vc/article/view/10.1186-2045-824X-4-14>. Date accessed: 14 apr. 2021. doi: http://dx.doi.org/10.1186/2045-824X-4-14.